The cases of Omicron are increasing all over the world. Meanwhile, there is news of relief that a vaccine is being made especially for Omicron in the country. It is being developed by Pune -based company Genova Biopharmaceuticals. The company says that the data from the second phase of clinical trials of the vaccine has been sent to the Central Drug Standard Control Organization (CDSCO). The human trial will be done soon as soon as permission is given. The new vaccine is mRNA-based. There are many hopes for this vaccine. The first reason for this is that it is being prepared in India and secondly, it has been prepared for Omicron.

What is so special about this vaccine is that it will beat Omicron, when will it be ready and where such variant-specific vaccines are being made, know the answers to these questions…

What is mRNA Vaccine?

According to the report of Firstpost, this vaccine is based on mRNA. Understand in simple language, through this type of vaccine, a small part of the genetic code (RNA) of the virus’s body is injected into the human being. Through this vaccine, a message is sent to the cells of the human body that if something like this genetic code reaches, then the immune system fighting diseases should take immediate action to eliminate it. This vaccine does not contain a virus, but its genetic code is used, which would have caused any harm to the common man. In this way, after taking the vaccine, the human body becomes ready to beat the virus.

When will this vaccine be ready?

According to the news agency Reuters, this vaccine of Genova Biopharma, specially made for Omicron, can be completely ready within a month or two. Dr. VK Paul, head of the Kovid Task Force, says, this vaccine is special and is also a big achievement for the country.

Only a few countries have such a vaccine

Only a few countries in the world have a vaccine specially made for the variant. India is also included in them. Recently, the American company Pfizer has made a statement that it is developing a vaccine against Omicron and it will be fully prepared by March. Apart from this, Moderna and AstraZeneca are also trying to prepare variant-specific vaccines.

According to Dr. Sanjay Singh, CEO of Genova Biopharmaceuticals, the vaccine can be prepared quickly and easily with mRNA technology. Just as the virus is rapidly mutating, vaccines can also be developed against it.